Reporter brief
Senolytic treatment improved motor function and reduced neuronal damage in TDP-43 ALS mice
What happened
This animal study investigated cellular senescence in TDP-43Q331K mice, a genetic model of amyotrophic lateral sclerosis. Researchers treated mice with dasatinib and quercetin (senolytics) and found improvements in motor behavior, neuromuscular function, reduced axonal damage measured by plasma neurofilament light chain, enhanced motor cortex excitability, and preserved layer V neuron counts compared to controls.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Preclinical; Animal.
TDP-43Q331K mice (genetic ALS model)
- Design
- Preclinical
- Sample
- —
- Journal
- Neurobiology of disease
- Published
- Sep 18, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.